Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Hospitalization 39% Corwin et al. Bamlanivimab/e.. for COVID-19 EARLY Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 6,117 patients in the USA (November 2020 - January 2021) Lower hospitalization with bamlanivimab/etesevimab (p=0.00044) Corwin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305 Favors bamlanivimab/e.. Favors control

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Corwin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305
Corwin et al., The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305
Jun 2021   Source   PDF  
  All Studies   Meta
Retrospective 780 bamlanivimab patients and 5,337 patients not receiving treatment, showing lower hospitalization and ER visits with treatment.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to receive adjuvant treatments that are not tracked in the data (e.g., nasal/oral hygiene [, (B)], vitamin D [ (C)], etc.) — either because the physician recommending bamlanivimab/etesevimab also recommended them, or because the patient seeking out bamlanivimab/etesevimab is more likely to be familiar with the efficacy of additional treatments. Therefore, these kind of studies may overestimate the efficacy of treatments.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, 80.5% lower, RR 0.20, p = 0.08, treatment 1 of 780 (0.1%), control 35 of 5,337 (0.7%), NNT 190.
risk of hospitalization, 39.4% lower, RR 0.61, p < 0.001, treatment 57 of 780 (7.3%), control 490 of 5,337 (9.2%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Corwin et al., 10 Jun 2021, retrospective, USA, peer-reviewed, 8 authors, study period 23 November, 2020 - 17 January, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: Open Forum Infectious Diseases BRIEF REPORT The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting Douglas S. Corwin,1 Peter T. Ender,2 Nitasa Sahu,1 Ryan A. Durgham,3 Dennis M. McGorry Jr.,4 Awan Rahman,1 Jill Stoltzfus,5 and Jeffrey A. Jahre2 1 Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality. Keywords. bamlanivimab; COVID-19; treatment; outcomes. Limited ambulatory treatment options exist for coronavirus disease 2019 (COVID-19), the syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which contributes to the profound morbidity and mortality associated with this illness [1, 2]. The striking number of people afflicted with COVID-19 has resulted in a dramatic increase in health care resource requirements. More than a third of Americans live in locations with a critical bed shortage during a surge of cases of COVID-19, including metropolitan areas in the Middle Atlantic and Northeastern States [3]. This high degree of health care utilization has led to concerns about the quantity of resources available and ability to maintain a proper standard of care. In November 2020, bamlanivimab (LY-CoV555; Lilly), an IgG1 monoclonal antibody that binds to the receptor-binding Received 30 March 2021; editorial decision 1 June 2021; accepted 9 June 2021. Correspondence: D.S. Corwin, MD, St Luke’s University Health Network, 709 Delaware Ave, Fountain Hill, PA 18015 ( Open Forum Infectious Diseases®2021 © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact DOI: 10.1093/ofid/ofab305 METHODS St. Luke’s University Health Network (SLUHN) includes 12 hospitals, 76 primary care sites, and 18 urgent care centers in Eastern Pennsylvania and Western New Jersey. Testing for COVID-19 occurred at dedicated outpatient testing sites and emergency departments within the St. Luke’s Network. The analysis included patients treated with a single dose of 700 mg of bamlanivimab infused over 60 minutes from November 23, 2020, until January 17, 2021. Due to limited seat availability for infusion, in the setting of a large surge of patients in the region, only patients who were ≥65 years of age and/or had a BMI ≥35 with a positive COVID-19 test by polymerase chain reaction (PCR) within 7 days of symptoms received bamlanivimab treatment. One bamlanivimab infusion center is in Eastern Pennsylvania, and the other is in Western New Jersey. Referral for treatment was at the discretion of the primary care physician (PCP). A follow-up visit occurred 48 hours after the infusion with a PCP within SLUHN to..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop